13 August 2018
Immunicum AB (publ) presents preclinical data for ilixadencel in combination with checkpointhämmare and immunaktiverare in 2018, the year’s ESMO congress
Immunicum AB (publ; IMMU.ST) announced today that the company will present a poster about its leading product candidate, ilixadencel, in 2018, the year congress
The European Society for Medical Oncology (ESMO)
to be held on 19-23 October 2018 in Munich, Germany. Immunicum will publish the full data in a press release that follows after the presentation. A summary of the poster will also be published in the ESMO 2018 Congress Abstract Book, a supplement to ESMO’s official yearbook,
The Annals of Oncology.
Title: Intratumoral administration of pro-inflammatory allogeneic, «off-the-shelf,» dendritic cells in combination with anti-PD-1 or anti-CD137 has a synergistic anti-tumor effect (Intratumoral administration of pro-inflammatory allogeneic dendritic cells that can be stored «on the shelf» («off-the-shelf») in combination with anti-PD-1 or anti-CD137 has a synergistic anti-tumor effect)
Presenter: Dr. Alex Karlsson-Parra, Immunicums director of research
Date & time: Monday, 22 October 2018; there is a 12.45-13.45 CET
Location: Hall A3 — Items Area Networking Hub
Cellterapiprodukten ilixadencel is a cancerimmunaktiverare that can be stored «on the shelf» («off-the-shelf») and has been developed for the treatment of solid tumors. The active ingredient is activated allogeneic dendritic cells taken from healthy donors. Intratumoral injection of these cells gives rise to an inflammatory response, which in turn leads to a tumor-specific activation of the patient’s cytotoxic T-cells.
For further information, please contact:
Carlos de Sousa, CEO, Immunicum
Telephone: +46 (0) 31 41 50 52
Michaela Gertz, Cfo, Immunicum
Telephone: +46 (0) 70 926 17 75
Gretchen Schweitzer, and Joanne Tudorica
Telephone: +49 172 861 8540
About Immunicum AB (publ)
Immunicum is establishing a unique approach within the immunonkologi through the development of the storable allogeneic cell-based therapies. Our goal is to fight cancer by activating and strengthening the patient’s own immune system, and thus improve the survival and quality of life. The company’s leading product, ilixadencel, consisting of the pro-inflammatory allogeneic dendritic cells, have the potential to become a backbone of modern combination therapy of several solid tumors. Immunicum is founded and based in Sweden, and is listed on Nasdaq Stockholm. www.immunicum.com
20180813_Immunicum_ESMO items acceptance_SWE_Final
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Immunicum AB via Globenewswire